Medtronic announces clearance of Hugo RAS by FDA for urological procedures

Medtronic (MDT) announced the FDA has cleared the Hugo robotic-assisted surgery, or RAS, system for use in urologic surgical procedures. The Hugo RAS system’s clearance brings a versatile robotic-assisted platform to U.S. surgeons and health systems seeking to expand soft-tissue robotic surgery programs and access to minimally invasive care. The U.S. leads the world in robotic surgery adoption, yet hospitals continue to face challenges in capacity and access. The introduction of the Hugo RAS system in the U.S. helps address this gap, offering an innovative approach to robotic-assisted surgery from the global leader in surgery and bringing choice to hospitals and surgeons across the country. Thoughtfully designed with input from surgeons and hospital administrators to shape the future of surgery, the Hugo RAS system includes three main differentiators: Modular Design; Digital Ecosystem; and Differentiated Partnership. With FDA clearance, the Hugo RAS system is indicated for use in minimally invasive urologic surgical procedures including prostatectomy, nephrectomy, and cystectomy – common procedures that account for about 230,000 surgeries per year in the U.S.